PLRX (NASDAQ) - Pliant Therapeutics Inc

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US7291391057
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase IIa trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. It also develops PLN-1474, a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. Web URL:

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for PLRX (NASDAQ) - Pliant Therapeutics Inc


Market Cap in USD 1,005m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2020-06-03


Fundamental -
Dividend -
Performance 5y -2.23
Rel. Performance vs Sector -4.36
Analysts 4.64
Fair Price Total Ret. 15.68
Fair Price DCF todo


Growth TTM -16.47%
CAGR 5y -6.00%
CAGR / Mean Drawdown 5y -0.14
Sharpe Ratio TTM -0.35
Alpha vs SP500 TTM -35.49
Beta vs SP500 5y weekly 0.97
CAPM 7.43%
Average Daily Range 2m 4.70%
Reversal Oscillator 75.32
Volatility GJR Garch 1y 113.57%
Price / SMA 50 1.4%
Price / SMA 200 -24.15%
Current Volume 886.4k
Average Volume 20d 727.4k


Yield TTM 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Consistency of Dividends all time 0.0%